Skip to main content

RHYTHM PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

​​​​​​​​​
​ · ​ · ​ · ​ · Incorporated by Reference
ExhibitNumber · Exhibit Description · Form · Date · Number
3.1​Amended and Restated Certificate of Incorporation.​10-Q​05/04/2020​3.1
3.2​Amended and Restated Bylaws.​8-K​12/18/2023​3.1
3.3​Certificate of Designations​8-K​04/16/2024​3.1
3.4*​Amended and Restated Certificate of Designations​​​​​​
10.1*​Summary of Non-Employee Director Compensation Policy.​​​​​​
10.2‡‡​Exclusive License Agreement, dated January 4, 2024, by and between Rhythm Pharmaceuticals, Inc. and LG Chem, Ltd.​10-K​02/29/2024​10.25
10.3​Investment Agreement dated April 1, 2024, by and between Rhythm Pharmaceuticals, Inc., certain affiliates of Perceptive Advisors LLC, and certain other investors​8-K​04/01/2024​10.1
10.4*​Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan Performance Unit Agreement​​​​​​
10.5*​Third Amendment to Lease, dated May 2, 2024, by and between the Registrant and 500 Boylston & 222 Berkeley Owner (DE) LLC.​​​​​​
31.1*​Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).​​​​​​
31.2*​Certification of the Principal Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).​​​​​​
32.1**​Certification of the Principal Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).​​​​​​
32.2**​Certification of the Principal Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).​​​​​​
101.INS*​Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.​​​​​​
101.SCH*​Inline XBRL Taxonomy Extension Schema Document.​​​​​​
101.CAL*​Inline XBRL Taxonomy Extension Calculation Linkbase Document.​​​​​​
101.DEF*​Inline XBRL Taxonomy Extension Definition Linkbase Document.​​​​​​
101.LAB*​Inline XBRL Taxonomy Extension Label Linkbase Document.​​​​​​
101.PRE*​Inline XBRL Taxonomy Extension Presentation Linkbase Document.​​​​​​
104*​Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).​​​​​​
​​​​​​​​​
  • Filed herewith.

** Furnished herewith.

‡‡ Indicates that portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not material and the registrant customarily and actually treats such information as private or confidential.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.